Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference
Sagimet Biosciences (Nasdaq: SGMT) announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The clinical-stage biopharmaceutical company, which develops therapeutics for metabolic and fibrotic pathways, will present on Tuesday, December 3, 2024 at 10 a.m. EST in New York City. A webcast will be accessible through Sagimet's website, with replay available for 90 days after the event.
Sagimet Biosciences (Nasdaq: SGMT) ha annunciato la sua partecipazione alla 36ª Conferenza annuale sulla salute di Piper Sandler. L'azienda biofarmaceutica in fase clinica, che sviluppa terapie per percorsi metabolici e fibrotici, presenterà il martedì 3 dicembre 2024 alle 10:00 EST a New York City. Sarà disponibile un webcast tramite il sito web di Sagimet, con il replay accessibile per 90 giorni dopo l'evento.
Sagimet Biosciences (Nasdaq: SGMT) anunció su participación en la 36ª Conferencia Anual de Salud de Piper Sandler. La compañía biofarmacéutica en etapa clínica, que desarrolla terapias para vías metabólicas y fibrosas, presentará el martes 3 de diciembre de 2024 a las 10 a.m. EST en la ciudad de Nueva York. Habrá una transmisión en vivo accesible a través del sitio web de Sagimet, con repetición disponible durante 90 días después del evento.
사기멧 바이오사이언스 (Nasdaq: SGMT)는 파이퍼 샌들러 제36회 연례 헬스케어 콘퍼런스에 참여한다고 발표했습니다. 대사 및 섬유화 경로를 위한 치료제를 개발하는 임상 단계의 바이오제약 회사는 2024년 12월 3일 화요일 오전 10시 EST에 뉴욕시에서 발표할 예정입니다. 사기멧의 웹사이트를 통해 웹캐스트가 제공되며, 이벤트 후 90일 동안 재생할 수 있습니다.
Sagimet Biosciences (Nasdaq: SGMT) a annoncé sa participation à la 36ème Conférence annuelle sur la santé de Piper Sandler. La société bio-pharmaceutique en phase clinique, qui développe des thérapies pour les voies métaboliques et fibroses, présentera le mardi 3 décembre 2024 à 10h EST à New York. Un webinaire sera accessible via le site internet de Sagimet, avec une rediffusion disponible pendant 90 jours après l'événement.
Sagimet Biosciences (Nasdaq: SGMT) gab seine Teilnahme an der 36. jährlichen Healthcare-Konferenz von Piper Sandler bekannt. Das klinische biopharmazeutische Unternehmen, das Therapeutika für metabolische und fibrotische Wege entwickelt, wird am Dienstag, den 3. Dezember 2024 um 10 Uhr EST in New York City präsentieren. Ein Webcast wird über die Website von Sagimet zugänglich sein, mit einer Wiederholung, die 90 Tage nach der Veranstaltung verfügbar ist.
- None.
- None.
SAN MATEO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 10 a.m. EST in New York City, New York.
A webcast of the presentation will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into Phase 3 development in MASH. For additional information about Sagimet, please visit www.sagimet.com.
Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
Source: Sagimet Biosciences Inc.
FAQ
When is Sagimet Biosciences (SGMT) presenting at the Piper Sandler Healthcare Conference?
How long will the Sagimet Biosciences (SGMT) Piper Sandler Conference webcast be available?
Where can I watch Sagimet Biosciences' (SGMT) Piper Sandler Conference presentation?
What type of therapeutics does Sagimet Biosciences (SGMT) develop?
